LFCR Lifecore Biomedical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LFCR

Price (delayed)

$7.17

Market cap

$217.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.67

Enterprise value

$341.39M

Landec Corporation is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc.Landec designs, develops, manufactures and sells products for ...

Highlights
The company's quick ratio has surged by 65% YoY
Lifecore Biomedical's debt has decreased by 21% from the previous quarter and by 6% YoY
LFCR's EPS has shrunk by 96% YoY and by 18% QoQ
Lifecore Biomedical's net income has plunged by 85% YoY and by 30% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.landec.com
Peers: OGN

Key stats

What are the main financial stats of LFCR
Market
Shares outstanding
30.32M
Market cap
$217.41M
Enterprise value
$341.39M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.2
Price to sales (P/S)
1.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.17
Earnings
Revenue
$157.39M
EBIT
-$101.56M
EBITDA
-$87.78M
Free cash flow
-$39M
Per share
EPS
-$5.67
Free cash flow per share
-$1.29
Book value per share
$1.16
Revenue per share
$5.19
TBVPS
$7.19
Balance sheet
Total assets
$236.15M
Total liabilities
$163.44M
Debt
$126.94M
Equity
$34.21M
Working capital
$50.77M
Liquidity
Debt to equity
3.71
Current ratio
2.35
Quick ratio
0.94
Net debt/EBITDA
-1.41
Margins
EBITDA margin
-55.8%
Gross margin
19.5%
Net margin
-74.9%
Operating margin
-51.7%
Efficiency
Return on assets
-44.4%
Return on equity
-168.8%
Return on invested capital
-41.9%
Return on capital employed
-51.2%
Return on sales
-64.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LFCR stock price

How has the Lifecore Biomedical stock price performed over time
Intraday
-2.05%
1 week
-3.76%
1 month
1.13%
1 year
-15.75%
YTD
10.65%
QTD
-4.97%

Financial performance

How have Lifecore Biomedical's revenue and profit performed over time
Revenue
$157.39M
Gross profit
$30.66M
Operating income
-$81.4M
Net income
-$117.9M
Gross margin
19.5%
Net margin
-74.9%
Lifecore Biomedical's net margin has plunged by 96% YoY and by 38% from the previous quarter
Lifecore Biomedical's net income has plunged by 85% YoY and by 30% from the previous quarter
Lifecore Biomedical's gross profit has decreased by 42% YoY and by 18% QoQ
The company's gross margin fell by 38% YoY and by 13% QoQ

Growth

What is Lifecore Biomedical's growth rate over time

Valuation

What is Lifecore Biomedical stock price valuation
P/E
N/A
P/B
6.2
P/S
1.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.17
LFCR's EPS has shrunk by 96% YoY and by 18% QoQ
LFCR's equity has dropped by 76% year-on-year and by 54% since the previous quarter
LFCR's P/B is 63% above its last 4 quarters average of 3.8
The price to sales (P/S) is 23% lower than the 5-year quarterly average of 1.8 and 8% lower than the last 4 quarters average of 1.5
LFCR's revenue is down by 6% YoY and by 6% QoQ

Efficiency

How efficient is Lifecore Biomedical business performance
The ROA has plunged by 194% YoY and by 41% from the previous quarter
LFCR's ROS has shrunk by 108% YoY and by 41% QoQ
Lifecore Biomedical's ROE has plunged by 81% from the previous quarter
Lifecore Biomedical's return on invested capital has decreased by 34% QoQ

Dividends

What is LFCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LFCR.

Financial health

How did Lifecore Biomedical financials performed over time
LFCR's total assets is 44% more than its total liabilities
The company's quick ratio has surged by 65% YoY
The company's current ratio has surged by 60% YoY
LFCR's equity has dropped by 76% year-on-year and by 54% since the previous quarter
The debt to equity has soared by 71% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.